Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories : 2Q 2021 Earnings Infographic

07/22/2021 | 10:58am EDT

SECOND-QUARTER

2021 RESULTS

TOTAL COMPANY

$10.2B

+35%1

TOTAL COMPANY

ON AN

SALES WORLDWIDE

ORGANIC BASIS*

$1.17

REFLECTS OVER

105%3

ADJUSTED

GROWTH VERSUS

DILUTED EPS2

THE PRIOR YEAR

FULL-YEAR 2021 GUIDANCE REMAINS UNCHANGED ADJUSTED DILUTED EPS4

$4.30 TO $4.50

REFLECTS STRONG DOUBLE-DIGIT GROWTH

KEY BUSINESS UNITS5

ON AN ORGANIC BASIS*

+45.1% +57.2%

MEDICAL DEVICESDIAGNOSTICS

+9.5% +14.5%

NUTRITIONESTABLISHED PHARMACEUTICALS

BUSINESS HIGHLIGHTS

FREEST YLE LIBRE®†

43% growth in FreeStyle Libre on an organic basis6

World's leading7 continuous glucose monitoring system has nearly 3.5 million users worldwide

NUTRITION

16% growth in Adult Nutrition on an organic basis8

Pandemic continues to raise awareness of how good nutrition and hydration support immune health

DIAGNOSTICS

57% growth on anorganic basis9

Partnership with United Airlines enables international travelers to use BinaxNOWTM Home Test and NAVICATM app to return to the U.S. if they test negative

*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated July 22, 2021, available at www.abbottinvestor.com. 1. On a GAAP basis, second-quarter Abbott sales increased 39.5%. 2. Second-quarter GAAP diluted EPS was $0.66. 3. Second-quarter diluted EPS from continuing operations on a GAAP basis reflects 120% growth. 4. Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $2.75 to $2.95. Abbott forecasts specified items for the full-year 2021 of $1.55 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, including expenses to align its COVID-19testing-related business with current and projected demand, expenses associated with acquisitions and other net expenses. 5. On a GAAP basis, Medical Devices sales increased 51.3%; Diagnostics sales increased 62.8%; Nutrition sales increased 11.9%; Established Pharmaceuticals sales increased 16.4%. 6. On a GAAP basis, FreeStyle Libre increased 53%. 7. Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems. 8. On a GAAP basis, Global Adult Nutrition increased 18%. 9. On a GAAP basis, Diagnostics increased 63%. †Find important safety information about the FreeStyle® Libre portfolio: www.freestylelibre.us/safety-information.

‡The BinaxNOW™ COVID-19 Ag Card Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for prescription home use with self-collected observed direct anterior nasal (nares) swab samples from individuals aged 15 years or older who are suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset or adult collected nasal swab samples from individuals aged four years or older who are suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset. The BinaxNOW COVID-19 Ag Card Home Test is to be performed only with the supervision of a telehealth proctor.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Disclaimer

Abbott Laboratories published this content on 22 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 July 2021 14:57:10 UTC.


© Publicnow 2021
All news about ABBOTT LABORATORIES
09/15ABBOTT LABORATORIES : to Pay Quarterly Cash Dividend of $0.45 a Share on Nov. 15..
MT
09/15ABBOTT : Declares 391st Consecutive Quarterly Dividend
PR
09/15Abbott Laboratories Declares Quarterly Dividend, Payable on November 15, 2021
CI
09/13GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...
09/13INSIDER SELL : Abbott Laboratories
MT
09/10QIAGEN N : 3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate
RE
09/10QIAGEN N : supports White House COVID-19 vaccination, test mandate
RE
09/08INSIDER SELL : Abbott Laboratories
MT
09/03INSIDER SELL : Abbott Laboratories
MT
09/02ABBOTT LABORATORIES : Acquires Medical Device Company Walk Vascular
MT
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2021 39 807 M - -
Net income 2021 5 837 M - -
Net Debt 2021 8 454 M - -
P/E ratio 2021 38,4x
Yield 2021 1,35%
Capitalization 225 B 225 B -
EV / Sales 2021 5,86x
EV / Sales 2022 5,84x
Nbr of Employees 109 000
Free-Float 88,8%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 126,79 $
Average target price 130,04 $
Spread / Average Target 2,57%
EPS Revisions
Managers and Directors
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Miles D. White Executive Chairman
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES15.80%224 776
MEDTRONIC PLC10.72%174 552
BECTON, DICKINSON AND COMPANY4.69%75 229
HOYA CORPORATION30.10%62 323
ALIGN TECHNOLOGY, INC.34.62%56 839
SARTORIUS STEDIM BIOTECH79.60%56 591